

EXHIBIT 1

CLASS SETTLEMENT AGREEMENT

Dated February 13, 2026, by and between

Strides Pharma, Inc.

and

Representative Plaintiffs May Painter, Nicole Heslip, Mathias Conduff, Nathaniel Mendez-

Gutierrez, Rodney Shaw, Myles Thomason, and Jeffrey Duprex,

Individually and on behalf of the Settlement Class, through The Block Firm, LLC

CLASS SETTLEMENT AGREEMENT

This Class Settlement Agreement (“Agreement”) is made and entered into as of February 13, 2026, by and among the following parties (the “Parties”):

1. The Representative Plaintiffs, May Painter, Nicole Heslip, Mathias Conduff, Nathaniel Mendez-Gutierrez, Rodney Shaw, Myles Thomason, and Jeffrey Duprex, through Class Counsel (defined below), on behalf of themselves and each member of the proposed settlement class (“Settlement Class Members”) in *Painter v. Strides Pharma, Inc.* pending in the United States District Court for the Southern District of New York, No. 7:25-CV-4189 (the “Class Action”); and
2. Defendant Strides Pharma, Inc. (“Strides”).

WHEREAS, the Class Action was filed against Strides;

WHEREAS, Strides denies the claims asserted in the Class Action, including all charges of liability arising out of the allegations therein;

WHEREAS, Strides believes it has defenses to the factual allegations and legal claims in the Class Action and to class certification and believes those defenses to have merit; nonetheless, Strides desires to resolve the Class Action to avoid the costs, burdens, and risks of litigation;

WHEREAS, the Representative Plaintiffs have asserted legal Claims in the Class Action and believe those claims to have merit; nonetheless, Representative Plaintiffs and Class Counsel recognize that, having conducted an assessment of relevant documents and information, they believe that the benefits provided by this Agreement are fair and reasonable, compare favorably to the expected result of further litigation, and avoid the costs and uncertainty of protracted litigation, and they desire to resolve the Class Action;

WHEREAS, the Parties desire to fully and finally settle the Class Action in the manner and upon the terms and conditions set forth in this Agreement.

NOW, THEREFORE, IT IS HEREBY STIPULATED AND AGREED by and among the Representative Plaintiffs (for themselves and all Settlement Class Members as defined herein) through Class Counsel, and by Strides, all intending to be legally bound hereby, that, subject to the approval of the Court, the Class Action shall be fully and finally resolved, compromised, discharged, and settled among the Parties under the following terms and conditions:

I. DEFINITIONS

A. Class Definition

The Settlement Class is defined as follows:

All natural persons in the United States who purchased Strides Testosterone Gel, for personal or household use, from June 1, 2022, until July 31, 2025.¹

B. Defined Terms

1. Strides Testosterone Gel – testosterone gel manufactured by or on behalf of Strides and sold under NDCs 64380015102 and 64380015202.

2. Claims Administrator – the third party engaged by Strides to administer the Settlement Refund Program. Subject to the Court’s approval, Strides has selected Verita Global to serve as Claims Administrator.

3. Claims Period – the time during which Settlement Class Members may submit claims to the Settlement Refund Program, which shall commence concurrently with the implementation of the Notice Plan and shall end sixty (60) days after the commencement of the Claims Period.

¹ Specifically excluded from the Class are Strides, Strides’ officers, directors, agents, trustees, parents, children, corporations, trusts, representatives, employees, principals, servants, partners, joint ventures, or entities controlled by Strides, and any of its heirs, successors, assigns, or other persons or entities related to or affiliated with Strides and/or Strides’ officers and/or directors, the judge assigned to this action, and any member of the judge’s immediate family.

4. Class Claims – all claims pleaded on behalf of the putative class in the Class Action.
5. Class Counsel – the attorneys representing Plaintiffs in the Class Action, including Aaron Block and Max Marks of The Block Firm LLC, collectively referred to as “Class Counsel.”
6. Class Counsel Fees – any award of attorneys’ fees and costs as further described in Section VI herein and subject to the approval of the Court.
7. Class Period – June 1, 2022, to July 31, 2025.
8. Court – the United States District Court for the Southern District of New York and the Honorable Nelson S. Román.
9. Final – means that the Final Order and Judgment has been entered on the docket in the Class Action, and all of the following shall have occurred: (i) the expiration of the time to file a motion to alter or amend the Final Order and Judgment under Federal Rule of Civil Procedure 59(e) without any such motion having been filed or, if such a motion is filed, the entry of an order denying such motion; and (ii) the time in which to appeal the Final Order and Judgment has passed without any appeal having been taken or, if an appeal is taken, immediately after (a) the date of the final dismissal of any appeal or the final dismissal of any proceeding on certiorari, or (b) the date of affirmance of the Final Order and Judgment on appeal and the expiration of time for any further judicial review whether by appeal, reconsideration, or petition for a writ of certiorari and, if certiorari is granted, the date of final affirmance of the Final Order and Judgment following review pursuant to the grant.
10. Final Order and Judgment – an Order of the Court fully and finally approving the Settlement and dismissing the Class Action with prejudice.
11. NDC – National Drug Code as defined in 21 C.F.R. § 207.33.

12. Notice – the Notice of Class Action Certification and Proposed Class Action Settlement provided to the Settlement Class Members pursuant to Section VIII.A of this Agreement.

13. Notice Plan – the plan for satisfying the Rule 23 and Constitutional Due Process requirements for notice to the Class, prepared by the Claims Administrator and to be attached as an exhibit to Plaintiffs’ Motion for Certification of the Settlement Class and for Preliminary Approval of Class Action Settlement.

14. Objection and Opt-Out Deadline – the date by which Settlement Class Members must submit a written statement of any objections to the Settlement to the Court or notify the Claims Administrator that they are opting out of the Settlement.

15. Parties – Strides, Representative Plaintiffs, and Settlement Class Members.

16. Preliminary Approval Date – the date on which the Court enters the Preliminary Approval Order.

17. Preliminary Approval Order – the Order of the Court preliminarily approving the Settlement Class, Proposed Class Action Settlement, and the Notice of Class Certification and Proposed Class Action Settlement.

18. Product Recall – a recall of Strides Testosterone Gel, due to benzene content, initiated by Strides pursuant to 21 C.F.R. Part 7, subpart C, and published in FDA’s Enforcement Reports on March 5, 2025, as reflected by Exhibit 2 to the Complaint.

19. Proof of Purchase – proof that a Settlement Class Member purchased a prescription of Strides Testosterone Gel during the Class Period, according to the terms set forth in Section II.ii.

20. Released Claims – any and all economic loss claims, known or unknown, that were, could have been, or may be brought, now or in the future, by or on behalf of any Settlement Class

Member, against any and all Released Parties, that arise out of or relate to the allegations in the Class Action. As described in Section IV herein, Released Claims expressly exclude any personal injury and/or wrongful death claims.

21. Released Parties – Strides, and its past, present, and future parents, subsidiaries, domestic and foreign corporations, divisions, affiliates, partners, joint venturers, dealers, distributors, repackagers, private label distributors, manufacturers, active and excipient ingredient suppliers, service providers, stockholders, predecessors, successors, assigns, and insurers, and the past, present, and future officers, directors, managers, employees, attorneys, agents, assigns, and representatives of each of the foregoing and any other person, firm, or corporation, domestic or foreign, with whom any of them is now or may hereafter be affiliated, and any other affiliated person or entity, whether individual, corporate, or otherwise, and each of them.

22. Representative Plaintiffs – May Painter, Nicole Heslip, Mathias Conduff, Nathaniel Mendez-Gutierrez, Rodney Shaw, Myles Thomason, and Jeffrey Duprex, on or behalf of themselves and each Settlement Class Member.

23. Settlement – the settlement embodied in this Class Settlement Agreement.

24. Settlement Class – the class to be approved by the Court in the Preliminary Approval Order and Final Order and Judgment.

25. Settlement Class Members – those members of the Settlement Class, excluding opt-outs.

26. Settlement Refund Program – the program for payment of claims made during the Claims Period arising from the purchase of Strides Testosterone Gel during the Class Period, as further described in Section II.

II. SETTLEMENT REFUND PROGRAM

Concurrently with implementation of the Notice Plan, the Claims Administrator shall commence a process whereby Settlement Class Members may submit claims to and recover from the Settlement Refund Program for Strides Testosterone Gel purchased by Settlement Class Members during the Class Period. Payments to claiming Settlement Class Members will not be disbursed unless and until the Final Order and Judgment becomes Final. The Settlement Refund Program shall be subject to the following parameters:

- i. **Eligibility:** Any natural person who purchased a prescription of Strides Testosterone Gel between June 1, 2022, and July 31, 2025, and who can meet the Proof of Purchase requirements below.
- ii. **Proof of Purchase:** Proof of purchase can be shown through any reliable means sufficient to establish (1) the individual making the purchase, (2) the date the purchase was made, (3) a NDC number or other manufacturer identification showing that the testosterone gel was Strides Testosterone Gel, and (4) the amount paid out-of-pocket, if any. For example, an individual could show proof of purchase through a download or printout from their pharmacy, insurance company, or pharmacy benefits manager that includes the details above or by providing the original or a copy of the purchase receipt.
- iii. **Reimbursement:** Eligible Settlement Class Members may receive payment for each purchase of Strides Testosterone Gel, as set out below:
 1. **Purchases from January 1, 2025, through July 31, 2025:** Settlement Class Members can recover 100% of their out-of-pocket payments for each prescription.

2. **Purchases from January 1, 2024, through December 31, 2024:** Settlement Class Members can recover 75% of their out-of-pocket payments for each prescription.
 3. **Purchases before 2024:** Settlement Class Members can recover 40% of their out-of-pocket payments for each prescription.
 4. **Minimum Payment:** Settlement Class Members with no out-of-pocket payments or minimal out-of-pocket payments can receive \$3.50 per applicable prescription, as modified by the percentages above based on purchase date.
- iv. **Length of Claims Period:** The Claims Period for the Settlement Refund Program will commence concurrently with implementation of the Notice Plan, and all claims by Settlement Class Members must be received by the Claims Administrator (if sent electronically) or postmarked (if sent by the United States Postal Service or a commercial mail carrier) by 11:59PM Eastern Time on the date sixty (60) days from the date of commencement of the Claims Period.
 - v. **Publication:** The availability of the Settlement Refund Program will be published as part of the Notice Plan pursuant to Section VIII.A herein.
 - vi. **Administration:** Strides will be responsible for engaging the Claims Administrator and for all costs associated with conducting and managing the Settlement Refund Program.

III. NON-REVERSIONARY FUND

Regardless of how many claims are made, Strides agrees to pay a minimum of \$750,000 to the Settlement Class into the Court registry or such other depository as the Court may direct.

If the claims made by the Settlement Class exceed \$750,000, Strides will pay the full amount of the claims, calculated as set out in Section II above. If the claims made by the Settlement Class fall below \$750,000, an additional amount will be distributed from the non-reversionary fund to each member of the Settlement Class pro rata based on the value of each individual's claims. If the Court finds that pro rata distribution of the full amount of the non-reversionary fund to members of the Settlement Class is not appropriate for any reason, the parties agree to meet and confer and propose for the Court's consideration an appropriate charity to receive a *cy pres* distribution of any remaining portion of the non-reversionary fund that is not distributed to members of the Settlement Class.

IV. REFORMULATION OF DRUG

After the Product Recall, Strides reformulated its product to replace the use of Carbomer 940. Strides agrees that it will not return to using Carbomer 940 in the manufacture of the product and will implement measures to prevent the release of testosterone gel with benzene levels above the applicable threshold.

V. RELEASED CLAIMS

This Agreement fully resolves and releases the Released Parties from all Released Claims. Class Counsel and the Representative Plaintiffs acknowledge that they have not sought compensation for personal injury and/or wrongful death on behalf of the putative class in the Class Action. This Settlement shall have no impact on the common law and/or statutory right of any Settlement Class Member or Settlement Class Member's representative to pursue personal injury and/or wrongful death claims in the event that a Settlement Class Member alleges to have suffered personal injury or wrongful death as a result of using Strides testosterone gel.

VI. CLASS COUNSEL FEES AND REPRESENTATIVE PLAINTIFF INCENTIVE AWARDS

The Parties understand that Class Counsel intends to seek reasonable Class Counsel Fees and incentive awards for the Representative Plaintiffs in connection with this Class Action Settlement via a petition with the Court. The Parties have no agreement regarding entitlement to or the amount of any Class Counsel Fees or incentive awards for the Representative Plaintiffs. Strides retains the right to contest any or all requested Class Counsel Fees and/or the Representative Plaintiffs' requested incentive awards. If so ordered, Strides agrees to pay any Class Counsel Fees, representative plaintiff incentive awards, and litigation costs ordered by the Court. Strides further agrees that any such payment will be separate from claims paid to the Settlement Class and will not be made out of or otherwise diminish the non-reversionary fund described in Section III or any other amounts due to the Settlement Class.

If applicable, Strides will pay Class Counsel Fees within sixty (60) days after the later of (a) the Court's approval of a fee petition and (b) the Final Order becoming Final, provided that Strides and Class Counsel may agree to payment in two equal installments, with the first occurring within the foregoing sixty (60) day period and the second occurring within ninety (90) days thereafter. If applicable, Strides will pay the Representative Plaintiffs' incentive awards within thirty (30) days after the later of (c) the Court's approval of a petition for a Representative Plaintiffs' incentive award and (d) the Final Order Becoming Final.

VII. MOTION FOR CERTIFICATION OF SETTLEMENT CLASS AND FOR PRELIMINARY APPROVAL OF CLASS ACTION SETTLEMENT

On or before February 13, 2026, pursuant to Federal Rule of Civil Procedure 23(e), Representative Plaintiffs shall file an unopposed Motion for Certification of the Settlement Class and for Preliminary Approval of Class Action Settlement that has been approved by Strides, together with a brief in support, this Agreement, and the Exhibits attached hereto, seeking entry of

an Order granting preliminary approval of the Settlement Class and the Settlement. The Proposed Order shall be in the form attached hereto as Exhibit A (“Proposed Preliminary Approval Order”).

The Proposed Preliminary Approval Order shall:

1. Grant preliminary certification of the Settlement Class;
2. Grant preliminary approval of this Settlement;
3. Authorize Notice of Class Certification and Preliminary Approval of Class Action Settlement; and
4. Schedule a final Settlement Hearing to review comments or objections concerning this Settlement; to consider its fairness, reasonableness and adequacy; and to determine whether entry of the Final Order and Judgment, substantially in the form described in Section IX, is appropriate. The Settlement Hearing shall be scheduled to give sufficient time for notice to be disseminated and to allow for objections pursuant to the terms of the Settlement.

VIII. NOTICE, BAR ORDER, OBJECTION DEADLINE

A. Notice of Class Certification and Class Action Settlement

No later than twenty-eight (28) days after the Court has (1) entered the Preliminary Approval Order, and (2) approved the form and method of Notice, Verita shall implement the Notice Plan. Notice shall also be published in any additional form as the Court shall direct; provided that the forms of Notice are substantially identical to the proposed Notice attached hereto as Exhibits B (Long-Form Notice) and C (Short-Form Notice).

B. CAFA Notice

Upon filing of the Motion for Certification of the Settlement Class and for Preliminary Approval of Class Action Settlement, Strides will provide timely notice of such motion as required by the Class Action Fairness Act, 28 U.S.C. § 1711 *et seq.*

C. Bar Order

Pursuant to the Final Order and Judgment, all Settlement Class Members will be bound by the terms of this Settlement, by the Court's Final Order and Judgment approving this Settlement, and by any order affirming the Court's Final Order and Judgment, if any appeal is made.

D. Objection and Opt-Out Deadline

Settlement Class Members and any other person or entity with standing to object who objects to this Settlement have a right to formally object or opt-out, as the case may be, not later than the Objection and Opt-Out Deadline, as follows. All objecting parties must submit a written statement of any objections to the Court. The written objections must be (1) physically received or (2) clearly postmarked by the United States Postal Service or a commercial mail carrier, no later than sixty (60) days after the deadline for publishing the Notice. Each objection must include the case name *Painter v. Strides Pharma, Inc.*, Case No. 7:25-CV-4189; (ii) the name, address and telephone number of the objector; (iii) the name, address, and telephone number of all counsel (if any) who represent the objector, including any former or current counsel who may be entitled to compensation for any reason if the objection is successful, and all legal factual support for the right to such compensation; (iv) documents or testimony sufficient to establish membership in the Settlement Class; (v) a detailed statement of any objection asserted, including the grounds therefor; (vi) whether the objector is, and any reasons for, requesting the opportunity to appear and be heard at the Final Approval hearing; (vii) the identity of all counsel (if any) representing the objector who will appear at the final approval hearing and, if applicable, a list of all persons who will be called to testify in support of the objection; (viii) copies of any papers, briefs, declarations, affidavits, or other documents upon which the objection is based; (ix) a detailed list of any other objections submitted by the Settlement Class Member, or his/her counsel, to any class actions submitted in any state or federal court in the United States in the previous five years (or

affirmatively stating that no such prior objection has been made); and (x) the objector's signature, in addition to the signature of the objector's attorney (if any) -- an attorney's signature alone shall not be deemed sufficient to satisfy this requirement. Failure to include documents or testimony sufficient to establish membership in the Settlement Class shall be grounds for overruling and/or striking the objection on grounds that the objector lacks standing to make the objection. Failure to include any of the information or documentation set forth in this paragraph also shall be grounds for overruling an objection.

Settlement Class Members who wish to opt-out must do so in writing mailed to the Claims Administrator, stating that they wish to be excluded from the Settlement Class. The written exclusion must be (1) physically received or (2) clearly postmarked by the United States Postal Service or a commercial mail carrier, no later than sixty (60) days after the deadline for publishing the Notice.

IX. FAIRNESS HEARING

Representative Plaintiffs shall ask the Court to set the Settlement Hearing for a date that is not earlier than fifteen (15) days after the Objection and Opt-Out Deadline (the "Settlement Hearing Date"). On or before the Settlement Hearing Date, Representative Plaintiffs shall move the Court for the entry of a Final Order and Judgment.

The Final Order and Judgment shall include:

1. Final approval of the Settlement Class;
2. Final approval of this Settlement in its entirety as fair, reasonable, and adequate, and in the best interests of the Class as a whole;
3. A determination that all Settlement Class Members shall be bound by the Settlement and shall be deemed conclusively to have settled and released with prejudice the Released Parties and to have covenanted not to sue the Released Parties;

4. A bar Order precluding each Settlement Class Member from asserting any and all Released Claims against any Released Parties in any court;
5. Dismissal of all Released Claims with prejudice as to the Released Parties; and
6. Reservation of the Court's continuing and exclusive jurisdiction over the Parties to administer, supervise, interpret, and enforce this Agreement in accordance with its terms.

X. DISMISSAL OF CLAIMS AND RELEASE

Upon entry of the Final Order and Judgment, all Class Claims, including all claims asserted by the Representative Plaintiffs in their individual capacities, shall be dismissed with prejudice and all Settlement Class Members shall be deemed to have unconditionally, fully, finally, and forever remised, released, relinquished, compromised, and discharged all Released Claims that were or could have been asserted against the Released Parties, whether or not any particular Settlement Class Member actually receives a payment described in Section II.

XI. COVENANT NOT TO SUE AND NON-SOLICITATION

Representative Plaintiffs, Settlement Class Members, and Class Counsel agree and covenant not to sue or to prosecute, institute or cooperate in the institution, commencement, filing, or prosecution of any lawsuit, appeal, arbitration or other proceeding relating to or based on any claim that concerns, arises out of or relates to any of the facts, actions, claims, allegations, events, transactions, occurrences, courses of conduct, representations, omissions, circumstances or other matters alleged or referred to, or which could have been alleged or referred to in the Class Action, with respect to the Released Parties.

Notwithstanding the above language, this Settlement shall have no impact on the common law and/or statutory right of the Representative Plaintiffs, Settlement Class Member, or Settlement Class Member's representative to pursue personal injury and/or wrongful death claims in the event

that the Representative Plaintiffs or a Settlement Class Member alleges to have suffered personal injury or wrongful death as a result of using Strides testosterone gel.

XII. RIGHT TO TERMINATE

This Agreement may be terminated upon written notice within fourteen (14) days after any one of the following events:

1. If the Court denies preliminary approval of the Settlement or refuses to preliminarily approve the Settlement without requiring material changes to the Notice attached as Exhibits B (Long-Form Notice) and C (Short-Form Notice) to this Agreement.

2. If the Court denies final approval of the Settlement or refuses to finally approve the Settlement without requiring material changes to the provisions contained in the Final Order and Judgment as set forth in Section IX herein, in order to enter the Final Order and Judgment.

3. The Final Order and Judgment is materially modified or reversed on any writ or appeal.

4. Strides, at its sole discretion, may terminate this Agreement if at least five (5) Settlement Class members represented by counsel properly file objections to the Settlement; at least twenty (20) Settlement Class Members represented pro se properly file objections to the Settlement; or if at least fifty (50) individuals meeting the Class Definition opt-out of the Settlement Class. Strides must notify Class Counsel of its intention to terminate the Agreement pursuant to this Section XI.5 no later than five (5) days after the Objection and Opt-Out Deadline.

In the event of any termination pursuant to the Agreement, the Parties shall be restored to their original positions.

XIII. STAY OF ALL PROCEEDINGS

The Parties will jointly obtain and shall continue to jointly seek an extension of a stay of all litigation pending entry of a Final Order and Judgment Approving this Settlement.

XIV. MISCELLANEOUS PROVISIONS

A. Not Evidence; No Admission of Liability

In no event shall this Agreement, in whole or in part, whether effective, terminated, or otherwise, or any of its provisions or any negotiations, statements or proceedings relating to it in any way be construed as, offered as, received as, used as or deemed to be evidence of the factual allegations and/or legal conclusions in the Class Action, in any other action, or in any judicial, administrative, regulatory or other proceeding. Without limiting the foregoing, neither this Agreement nor any related negotiations, statements or proceedings shall be construed as, offered as, received as, used as or deemed to be evidence or an admission or concession of liability or wrongdoing whatsoever or breach of any duty on the part of the Released Parties or any applicable defense, including without limitation any applicable statute of limitations. This Agreement does not constitute or reflect any admission of any liability by the Released Parties of the claims brought against them in the Class Action. No Party waives or intends to waive any applicable attorney-client privilege or work product protection for any negotiations, statements or proceedings relating to this Agreement.

Nothing in the preceding paragraph shall prevent a Party from using the Agreement or its provisions or, to the extent permitted by law, any negotiations, statements or proceedings related to the Agreement, to enforce the terms of the Agreement.

B. Confidentiality

The Parties agree that any and all documents, material, correspondence, and/or information received and/or produced or disclosed in furtherance of this Agreement, including all drafts of this Agreement (“Confidential Information”), shall be considered confidential and shall not be disclosed to any third parties, unless agreed upon in writing by the Parties or otherwise required by law. If a Party is required by law to disclose the Confidential Information of another Party, it must promptly

notify the Party whose Confidential Information is to be disclosed and provide that Party an opportunity to object to the disclosure.

C. Media/Public Statement Restrictions

To avoid contradictory, incomplete or confusing information about the Settlement during the Claims Period, the Parties agree that if they make any written press releases or statements to the media about the Settlement before the conclusion of the Claim Period, such releases or statements will be shared with the Parties in advance and, where desired by the other Party, made jointly.

Class Counsel will publish and maintain information on the firm's website regarding the Settlement and will otherwise work with the Claims Administrator as appropriate in connection with any Court-approved Notice Plan. If contacted by media, Plaintiffs and Class Counsel will refer them to the Settlement website and not comment further. Plaintiffs and Class Counsel shall make no statements, including statements to the press or any other public statements (excluding court filings that describe Plaintiffs' existing public allegations), that disparage Defendants, any Released Party, or any of the Covered Products, or accuse Defendants or any Released Party of any wrongdoing regarding this Settlement or Litigation or the subject matter thereof. Provided, however, that the foregoing term does not restrict Plaintiffs or Class Counsel with respect to otherwise proper judicial filings and does not require Plaintiffs or Class Counsel to amend or withdraw any of the same already filed.

D. Assignment of Claims

No Settlement Class Member will assign, or attempt to assign, to any persons any rights or claims related to the subject matter of the Class Action, including any Settlement proceeds. Any such assignment, or attempt to assign, to any person any rights or claims related to the subject

matter of the Class Action, including any Settlement proceeds, will be void, invalid, and of no force and effect, and the Claims Administrator will not recognize any such action.

E. Entire Agreement

This Agreement, including its Exhibits, contains an entire, complete, and integrated statement of each and every term and provision agreed by and among the Parties; it is not subject to any condition not provided for herein. This Agreement supersedes any prior agreements or understandings, whether written or oral, between and among the Representative Plaintiffs, the Settlement Class Members, Class Counsel, Strides, and/or counsel for Strides regarding the subject matter of the Class Action or this Agreement. This Agreement may be amended or modified only by a written instrument signed by or on behalf of Class Counsel and counsel for Strides and approved by the Court.

F. No Presumption Against Drafter

No Party shall be considered to be the drafter of this Agreement or any provision hereof for the purpose of any statute, case law, or rule of interpretation or construction that would or might cause any provision to be construed against the drafter hereof. This Agreement was drafted with substantial input by counsel for the Parties, and no reliance was placed on any representation other than those contained herein.

G. Force Majeure

Strides shall not be liable for delay or non-performance of its obligations under this Agreement arising from any act of God, governmental act, or act of terrorism, war, fire, flood, explosion, or civil riot. The performance of Strides' obligations under this Agreement, to the extent affected by the delay, shall be suspended for the period during which the cause of the delay persists.

H. Continuing and Exclusive Jurisdiction

The Court will have original and exclusive jurisdiction over all provisions of this Agreement, including the administration, supervision, interpretation, and enforcement of this Agreement in accordance with its terms and any award of attorney's fees.

I. Counterparts

This Agreement may be executed in counterparts, each of which shall constitute an original. Scanned signatures shall be considered valid signatures as of the date submitted, although the original signature pages shall thereafter be appended to this Agreement.

J. Divisions and Headings

The division of this Agreement into Sections and the use of captions and headings in connection herewith are solely for convenience and shall have no legal effect in construing the provisions of this Agreement.

K. Plurals and Singulars of Defined Terms

Where a term is defined in plural and used in singular in the text, it means one such. Where a term is defined in singular is used in plural in a text, it means more than one such.

L. Governing Law

This Agreement is to be interpreted according to the substantive law of the State of New York, without regard to its choice of law or conflicts of laws principles.

M. Waiver

The provisions of this Agreement may be waived only by an instrument in writing executed by the waiving Party. The waiver by any Party of any breach of this Agreement shall not be deemed to be or construed as a waiver of any other breach, whether prior, subsequent, or contemporaneous, of this Agreement.

N. No Third-Party Beneficiaries

Except as otherwise provided herein, nothing in this Agreement is intended, nor shall it in any way be construed, to create or convey any rights in or to any person other than the Representative Plaintiffs, Settlement Class Members, and the Released Parties.

O. Successors and Assigns

The provisions of this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns.

P. Authority and Acknowledgment

Each person signing this Agreement on behalf of a Party represents and warrants that he or she has all the requisite power and authority to enter into this Agreement and to implement the terms contemplated herein and is duly authorized to execute this Agreement on behalf of that Party. By their signature or counsel's signature affixed hereto, each Party acknowledges that he or she has read this Agreement, fully understands the agreements, representations, covenants, obligations, conditions, warranties, releases, and terms contained herein, and has had the advice of counsel pertaining thereto, prior to the time of execution. Class Counsel acknowledge that they have authority to execute this Agreement and bind the Representative Plaintiffs and Settlement Class Members.

Q. Construction

This Agreement shall be construed and interpreted to effectuate the Parties' intent, which is to resolve completely all Class Claims.

R. Notice

Any notices required under this Agreement shall be supplied by email and/or overnight courier as follows:


1. For the Certified Class, Notice shall be supplied to:

Aaron K. Block
Max Marks
The Block Firm LLC
309 East Paces Ferry Road, Suite 400
Atlanta, GA 30305
Telephone: (404) 997-8419
aaron@blockfirmllc.com
max.marks@blockfirmllc.com

2. For Strides, notice shall be supplied to:

Douglas Tween
John Eichlin
Linklaters LLP
1290 Avenue of the Americas
New York, NY 10104
Telephone: (212) 903-9072
douglas.tween@linklaters.com
john.eichlin@linklaters.com

So Agreed on Behalf of the Settlement Class Members and Class Counsel:



Aaron K. Block
The Block Firm LLC
309 East Paces Ferry Road, Suite 400
Atlanta, GA 30305

Executed on February 13, 2026.

So Agreed on Behalf of Strides Pharma, Inc.



Douglas M. Tween
Linklaters LLP

Executed on February 13, 2026.

ClassAction.org

This complaint is part of ClassAction.org's searchable [class action lawsuit database](#)
